Passage Bio, Inc. - Common Stock (PASG)
0.4009
+0.0034 (0.86%)
NASDAQ · Last Trade: Jul 12th, 3:18 AM EDT
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · July 11, 2025
Via Benzinga · July 10, 2025
Via Benzinga · June 26, 2025
Via Benzinga · May 12, 2025
Via Benzinga · April 30, 2025
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · April 3, 2025
Via Benzinga · March 27, 2025
Via Benzinga · March 19, 2025
Via Benzinga · March 13, 2025

Via Benzinga · January 2, 2025

Via Benzinga · November 29, 2024

Via Benzinga · October 25, 2024

Via Benzinga · September 2, 2024

PASG stock results show that Passage Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024

It's time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!
Via InvestorPlace · July 16, 2024

PASG stock results show that Passage Bio beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 14, 2024

PASG stock results show that Passage Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 6, 2024

Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.
Via InvestorPlace · February 1, 2024

Via Benzinga · January 26, 2024

Via Benzinga · January 22, 2024

Via Benzinga · January 17, 2024

Although nano-cap stocks are super-risky just like stealing bases in baseball, there may be a time and place for extreme speculation.
Via InvestorPlace · December 25, 2023

Via Benzinga · December 21, 2023

Shares of BlackBerry Limited (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results.
Via Benzinga · December 21, 2023

Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with
Via Benzinga · December 20, 2023